Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 83 publications
Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial data.
Journal: Endocrine-related cancer
Published: December 17, 2025
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.
Journal: Frontiers in oncology
Published: November 18, 2025
Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer.
Journal: Thyroid : official journal of the American Thyroid Association
Published: August 19, 2025
Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer.
Journal: JCO precision oncology
Published: April 23, 2025
Well-Differentiated Lung Neuroendocrine Tumor Masquerading as Metastatic Medullary Thyroid Cancer.
Journal: JCEM case reports
Published: March 10, 2025
A plain language summary looking at how well larotrectinib works and how safe it is for people with TRK fusion-positive thyroid cancer.
Journal: Future oncology (London, England)
Published: November 30, 2024
Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer.
Journal: Journal of patient-reported outcomes
Published: August 09, 2024
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 02, 2024
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy.
Journal: Endocrine-related cancer
Published: December 23, 2023
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
Journal: Thyroid : official journal of the American Thyroid Association
Published: December 08, 2023
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.
Journal: Journal for immunotherapy of cancer
Published: December 04, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Journal: Thyroid : official journal of the American Thyroid Association
Published: November 27, 2023
Last Updated: 09/26/2026